An innovative platform for pulmonary fibrosis

Fibrosing interstitial lung disease is a heterogeneous group of lung diseases associated with significant morbidity and mortality. Despite the number of clinical trials conducted over the past decade, only two therapies are currently approved to slow the progression of fibrosis. This article presents a new randomized multifactorial adaptive platform for drug development in fibrosing interstitial lung disease. The two main endpoints are forced vital capacity and 1-year mortality. This innovative and effective multi-interventional trial platform could speed up and improve the management of patients with fibrosing interstitial lung disease.